Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA

Urology

Volumn 53, Issue 6, 1999, Pages 1160-1167

  Jung, Klaus ^a   Brux, Brigitte ^a   Lein, Michael ^a   Knäbich, Angela ^a   Sinha, Pranav ^a   Rudolph, Birgit ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PROSTATE TUMOR; REPRODUCIBILITY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 0033151893     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00080-1     Document Type: Article

References (33)

1. 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
2. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem. 29:1991;787-794.
3. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
4. Catalona W.J. Clinical utility of measurements of free and total prostate-specific antigen (PSA) a review . Prostate. 7:(suppl):1996;64-69.
5. Van Iersel M.P., Witjes W.P.J., Thomas C.M.G., et al. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate. 7:(suppl):1996;48-57.
6. 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
7. Björk T., Piironen T., Pettersson K., et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology. 48:1996;882-888.
8. 1-antichymotrypsin complex . Clin Chem. 41:1995;1480-1488.
9. Wu J.T., Zhang P., Liu G.H., et al. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal. 12:1998;14-19.
10. Dai J., Zhou Z., Yeung K.K., et al. Measuring complexed PSA by an automated immunoassay to improve specificity. Clin Chem. 44:(suppl):1998;A45-A46.
11. Blijenberg B.G., Kessler A.C., Uhl W. Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen. Eur J Clin Chem Clin Biochem. 33:1995;965-973.
12. Blijenberg B.G., Eman I., Boeve E.R., et al. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-test PSA assay for prostate-specific antigen. Eur J Clin Chem Clin Biochem. 33:1995;383-392.
13. UICC . TNM Klassifikation maligner Tumoren. 4th ed. 1992;141 Springer, Berlin.
14. Meyer A., Jung K., Lein M., et al. Factors influencing the ratio of free to total prostate specific antigen in serum. Int J Cancer. 74:1997;630-636.
15. Lein M., Koenig F., Jung K., et al. Ratio of free prostate-specific antigen to total prostate-specific antigen in a population of 1160 healthy men. Br J Urol. 82:1998;231-236.
16. Kairisto V., Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest. 55:(suppl 222):1995;43-60.
17. Passing H., Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem. 21:1983;709-720.
18. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
19. Wu J.T., Wilson L., Zhang P., et al. Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal. 9:1995;15-24.
20. 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal. 12:1998;32-40.
21. Reiter W., Stieber P., Schmeller N., et al. Alpha 1-antichymotrypsin-PSA (ACT-PSA) a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate? Anticancer Res. 17:1997;4767-4770.
22. Paus E., Fossa S.D., Nilsson O., et al. The ratio of free to total PSA may be influenced by handling of serum samples. Anticancer Res. 15:1995;2402.
23. Wang T.J., Linton H.J., Payne J., et al. Development of monoclonal antibodies specific for the PSA-ACT complex and their incorporation into an immunoassay. Clin Chem. 43:1998;S225.
24. Wang T.J., Linton H.J., Payne J., et al. Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT. J Urol. 157:1997;147. (abstract).
25. Allard W.J., Zhou Z., Yeung K.K. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem. 44:1998;1216-1223.
26. Jung K., Stephan C., Lein M., et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 42:1996;1026-1033.
27. Lein M., Stephan C., Jung K., et al. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate - which cutoff should be used? Cancer Invest. 16:1998;45-49.
28. Vashi A.R., Wojno K.J., Henricks W., et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 49:1997;19-27.
29. 1-protease inhibitor in vitro. Prostate. 33:1997;87-96.
30. 1-anti-chymotrypsin. Prostate. 27:1995;166-175.
31. 1-antichymotrypsin. Clin Chem. 39:1993;2098-2103.
32. 1-antichymotrypsin in the plasma of patients with prostatic diseases. Eur Urol. 30:1996;512-518.
33. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 52:1998;372-378.